All24 hours
- All verticals
- Space
- Energy
- Quantum
- Robotics
- Cybersecurity
- Biotechnology
- Defense Tech
- Artificial Intelligence
Commerce tightens AI chip remote access rules as Nvidia halts China H200 shipments
Commerce's Bureau of Industry and Security issued an interim final rule restricting remote access to advanced AI chips for companies in countries of concern and rescinding the AI Diffusion Rule, with comments due January 20, 2027. Nvidia has halted licensed H200 shipments to China even as Treasury Secretary Bessent says the administration will keep the policy allowing approved sales. Sen. Tom Cotton is accusing Commerce Secretary Lutnick of ignoring smuggling warnings, and lawmakers are preparing more oversight of Nvidia's China business. · 20h ago
Forces, money & more AIIn the News
One card per story, every outlet that covered it25YesterdayYahooSenator proposes select committee on AI as Democrats hope to move quickly to regulate itColorado Sen. John Hickenlooper proposed a Senate select committee on AI and pressed the Senate leadership candidates to commit to a day-one AI regulation plan ahead of the next Congress.1 outletAILawmakers push AI safety bills after GAO chatbot attack-planning test20 linked 2d agoYahooCancer Vaccines Are Advancing. Can Regulators Keep Up?Reason Magazine argues that rapid advances in personalized cancer vaccines show the FDA's drug approval monopoly is ill-suited to fast-moving medicine and should be replaced by competing certification organizations. Biotech36 linked2 articles
- 2d agoYahooEarliestCancer Vaccines Are Advancing. Can Regulators Keep Up?
- 2d agoReasonPickupCancer Vaccines Are Advancing. Can Regulators Keep Up?
4d agoYahooWhite House pulls FDA nominee Heidi Overton after wavering support from Senate RepublicansSTAT's Readout Loud podcast episode covers the Trump administration withdrawing Heidi Overton's FDA commissioner nomination, the FDA's rejection of Summit Therapeutics and Akeso's lung cancer drug, and STAT's new index ranking China's largest drugmakers. Biotech66 linked4 articles · 2 outlets
- 4d agoSTATSTAT+: White House pulls nomination of Heidi Overton to lead FDA
- 4d agoYahooPickupWhite House pulls FDA nominee Heidi Overton after wavering support from Senate Republicans
- 3d agoSTATSTAT+: 7 burning questions about the FDA’s post-Overton future
- 2d agoSTATEarliestFDA’s search for a new leader, and China’s largest drugmakers
2d agoYahooSanders Sounds Warning Bell On Multifaceted Threats Posed By AI. He Could Influence The Democrats' AI Policy.Sanders used a Diary Of A CEO podcast interview to warn about AI's job, privacy and social risks and reaffirmed his support for the Ban Artificial Superintelligence Act and a pause on advanced AI.1 outletAILawmakers push AI safety bills after GAO chatbot attack-planning test18 linked 3d agoReasonBernie Sanders' 'Superintelligence' Ban Would Criminalize Today's AI for What Tomorrow's AI Might DoReason opinion argues the Sanders–Casar Ban Artificial Superintelligence Act would criminalize current AI for potential future capabilities, citing vague precursor traits and harsh penalties.1 outletAI9 linked 2d agoYahooFDA sets up council for post-market review of vaccines, gene therapiesFDA established the CBER Safety Council within its biologics center to formalize independent post-market safety review of approved vaccines, gene therapies and blood products, replacing the existing Safety Working Group.1 outletBiotech23 linked 3d agoFortuneThe midterms weren’t really about data centers. An AI researcher says voters want a pause on AI itselfFortune argues that Democrats, having won on anger over AI data centers and power bills, need to weigh moratoriums, congressional oversight, state utility cost rules, and tech-industry deals against the economic value of AI investment. AILoudoun County pauses data center approvals as states weigh limits after midterms56 linked2 articles
6d agoYahooBill Cassidy says Trump’s FDA pick faces uncertain committee voteSenate HELP Chair Bill Cassidy says he still has questions about FDA commissioner nominee Heidi Overton, leaving the outcome of Wednesday's committee vote uncertain.1 outlet19 linked 11d agoSTATSTAT+: Cassidy sets key vote on Overton, even as he remains undecided on nominee to lead FDASenate HELP Committee schedules a Nov. 18 vote on FDA commissioner nominee Heidi Overton, with Chair Bill Cassidy still undecided.1 outletBiotech6 linked 11d agoLos Angeles TimesInside the world of San Francisco 'peptide parties' — including one aboard a World War II shipHHS's enforcement discretion policy lets pharmacies compound six unapproved peptides ahead of a final FDA rule, which critics say expands access without adequate safety or efficacy evidence.1 outletBiotech12 linked 11d agoVanity FairLobbyists Are Preparing Silicon Valley Titans for Democratic Subpoenas and Congressional CrackdownVanity Fair reports that tech lobbyists are preparing Silicon Valley firms for expected Democratic congressional subpoenas and possible narrow AI, crypto, and antitrust crackdowns after the 2026 midterms.1 outletAI8 linked 11d agoSTATSTAT+: Democrats take new step toward investigating Trump’s drug pricing dealsIncoming Democratic committee chairs sent a fresh round of letters to all 27 drugmakers demanding details of their Trump administration most-favored-nation pricing deals.1 outlet5 linked 12d agoSTATSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionFDA ordered GLP-1 drug makers to add safety labeling warning patients and doctors of a potential risk of the rare eye condition NAION. Biotech17 linked2 articles
13d agoThe GuardianAnti-AI populism is the future of American politics | Garrison LovelyGarrison Lovely's Guardian opinion piece contends that voter backlash against AI datacenters and industry influence after the 2026 midterms makes anti-AI populism the defining political force heading into 2028.1 outletAILawmakers push AI safety bills after GAO chatbot attack-planning test25 linked 13d agoThe GuardianWe can’t just ‘move on’: Democrats must hold Trump accountable | Jan-Werner MüllerA Guardian opinion column urges Democrats, fresh from midterm wins, to hold the Trump administration accountable through testimony, impeachment and legal action rather than moving on. Democrats plan House oversight probes as Blanche won't rule out charges against Garcia13 linked2 articles
- 13d agoThe GuardianEarliestWe can’t just ‘move on’: Democrats must hold Trump accountable | Jan-Werner Müller
- 13d agoThe GuardianPickupTime to fight back: five leading thinkers on what Democrats should do post-midterms
13d agoThe Guardian‘A complete repudiation’: public health won big in US midterm electionsPublic health candidates and issues won broad support in the 2026 US midterm elections, with voters rejecting abortion restrictions and anti-trans measures mixed in results, according to a Guardian report.1 outlet7 linked 13d agoYahooUS FDA orders new eye risk warnings for Ozempic, ZepboundThe FDA ordered GLP-1 weight-loss and diabetes drugs such as Zepbound, Mounjaro, Ozempic and Wegovy to add a potential eye-risk warning (NAION) to their labeling.1 outletBiotech14 linked 13d agoYahoo · research by Food and Drug AdministrationFDA warns against online weight-loss drugs containing uncertain ingredientsFDA issued a warning letter to Cheap Medicine Shop and a safety alert on dosing errors, cautioning consumers about unapproved online semaglutide weight-loss injections.1 outletBiotech14 linked 13d agoAxiosTrump's AG won't rule out prosecuting Democrats who threaten to investigateBlanche refused on CNN and Fox to rule out criminal charges against Democratic lawmakers, including Rep. Robert Garcia, after Trump ordered DOJ to probe Democrats threatening investigations.1 outletDemocrats plan House oversight probes as Blanche won't rule out charges against Garcia11 linked 13d agoAxiosBlanche dismisses Means allegations as GOP's MAHA feud deepensBlanche brushed off Calley Means' corruption claims against Susie Wiles and her White House allies, as ex-FDA chief Marty Makary and Rep. Marlin Stutzman called for scrutiny of tobacco and kratom lobbying influence.1 outlet15 linked 13d agoPoliticoRep. Robert Garcia: ‘The days of us not fighting back are over’Ranking Democrat Rep. Robert Garcia pledged on CNN to launch Oversight Committee probes of Trump administration officials and family members, while Attorney General Todd Blanche condemned the plan as threats.1 outletDemocrats plan House oversight probes as Blanche won't rule out charges against Garcia12 linked 13d agoPoliticoSanders warns Democrats about spending too much time investigating TrumpSanders urges incoming Democrats to prioritize affordability over investigating Trump and says he will summon RFK Jr. before the HELP committee.1 outlet19 linked Nov 6AxiosEx-RFK Jr. adviser says Trump admin corruption prompted resignationFormer HHS adviser Calley Means says on Joe Rogan that corruption in the Trump administration, including alleged favoritism toward Bayer and lobbyist-linked funding priority, drove his resignation.1 outlet4 linked Nov 4Semafor‘Out for blood’: Investigations overshadow dealmaking in newly divided WashingtonSemafor reports that corporate America is readying executives for likely post-midterm Democratic congressional scrutiny over business dealings that courted President Trump. Democrats plan House oversight probes as Blanche won't rule out charges against Garcia51 linked7 articles
- Nov 2SemaforDemocrats weigh ‘lawfare’ against Trump
- Nov 2SemaforPickupDemocrats eye post-election powers
- Nov 3SemaforEarliestCorporate America prepares for post-midterm Democratic backlash
- Nov 4SemaforDemocrats turn scrutiny to tech CEOs and Trump officials
- Nov 4SemaforPickupDemocrats to focus on affordability and corruption probes
- Nov 4Semafor‘Out for blood’: Investigations overshadow dealmaking in newly divided Washington
- Nov 6SemaforDemocrats’ CEO targets remain a work in progress
Nov 4AxiosDemocrats will face a health care stress testAxios analysis says Democrats' post-election health care agenda, including Medicare for All votes and Medicaid cut rollbacks, will be constrained by limits and internal divisions.1 outlet9 linked
On the Hill
Congress, the White House and agencies13Ahead
Tuesday, Nov 24
Friday, Nov 27
Tuesday, Jan 5
11:59 PMAgencyFDAFDA is soliciting public feedback through docket FDA-2026-N-13135 on a discussion paper addressing how to weigh benefits and risks of autonomous and remotely teleoperated robotic medical devices, with comments due January 6, 2027.Comment deadlineRoboticsBiotechDetails13 linked 11:59 PMAgencyFDAFDA is taking public comments through January 2027 on a docket tied to a workshop about weighing benefits and risks of robotic medical devices that operate autonomously or via remote teleoperation.Comment deadlineRoboticsDetails13 linked
Recent
Wednesday, Sep 23
Sep 23CongressHouse Committee on the JudiciaryThe House referred the No Secrets for Data Centers Act (H.R. 10570) to the Judiciary Committee, with sequential referrals to Energy and Commerce and Ways and Means.none specifiedH.R. 10570AIDetails9 linked
Wednesday, Nov 18
3d agoAgencyFDAFDA's draft guidance on potency assessment for active immunotherapy products is open for public comment under docket FDA-2026-D-8561 until November 19, 2026.Comment deadlineBiotechDetails8 linked 4d agoCongressSenate Health, Education, Labor, and PensionsThe Senate HELP Committee has scheduled a business meeting to consider five executive nominees, including Heidi Overton for FDA Commissioner and James O'Neill for NSF Director.BiotechDetails12 linked 3d agoCongressCommittee on Health, Education, Labor, and PensionsSenate bill S. 5812 would permanently extend HHS authority to award priority review vouchers for rare pediatric disease products, and was referred to the HELP Committee on 2026-11-19.S. 5812BiotechDetails5 linked
Wednesday, Oct 21
Oct 21CongressCommittee on Energy and CommerceThe House referred H.R. 10857, a bill amending the FD&C Act and Public Health Service Act on next-generation clinical development, to Energy and Commerce with a secondary referral to Ways and Means.none specifiedH.R. 10857BiotechDetails4 linked
Friday, Aug 21
Aug 21CongressHouse Select Committee on the CCPTwo House Republicans on the China committee and an appropriations panel asked the FDA to bar Chinese trial data lacking a recent site audit, citing undisclosed deaths in Chinese gene-editing trials.BiotechDetails34 linked
Monday, May 19
May 19CongressCommittee on Energy and CommerceThe House referred H.R. 3521, the Clinical Trial Modernization Act, to the Energy and Commerce Committee and, sequentially, the Ways and Means Committee.noneH.R. 3521BiotechDetails3 linked
Friday, Oct 25
Wednesday, Mar 18
Mar 18CongressSenate Committee on Health, Education, Labor, and PensionsThe Senate HELP Committee held a hearing on S. 1387, the National Biotechnology Initiative Act of 2025, on March 19, 2026.S. 1387BiotechDetails3 linked
Nothing from this branch in view.
Times ET
Contracts
Solicitations, SBIR topics, grants and awards3GrantU.S. National Science Foundation3d agoNSF seeks research proposals under the Foundational Research in Robotics program, solicitation 27-501, with up to $20 million available.$20M ceilingCloses in 18260 daysNSF solicitation 27-501RoboticsLifecycle4 linked RFPDIRECTORATE FOR TECHNOLOGY, INNOVATION, AND PARTNERSHIPS (TIP)9d agoNSF seeks proposals for the NSF ELEGANT ecosystem for low-dimensional electronics growth, assembly, nanoelectronics, and translation.Closes in 26 daysNSF-OTASO-FY26-ELEGANTLifecycle4 linked GrantU.S. National Science Foundation10d agoNSF seeks proposals under solicitation 26-510 for SBIR/STTR Phase I, Phase II and Fast-Track awards with a $210 million ceiling, up to $2 million R&D per company.$210M ceilingCloses in 102 daysSolicitation 26-510Lifecycle5 linked